Anastasiya is a Senior Associate with F-Prime’s London team, focusing on healthcare investments. Prior to joining F-Prime in 2022, Ana was an Engagement Manager at McKinsey in London specializing in Pharmaceuticals & Medical Products. She had also worked as a Strategy Consultant at Advancy.
Ana holds a Ph.D. in Stem Cell Biology and Medicine from the University of Cambridge (UK), a MSc in Molecular and Cell Biology from École normale supérieure (Paris, France) and a BSc in Biology from Ivan Franko National University of Lviv (Ukraine).
Sarah Lamont is a Senior Associate at F-Prime, where she focuses on early-stage investments in fintech. Prior to joining F-Prime, she was a senior consultant at Oliver Wyman in the Private Capital & Financial Services practices, working with some of the world’s largest banks, private equity firms, and other financial institutions across the US and Europe.
In addition to her role at F-Prime, Sarah also co-leads the Boston chapter of the Emerging Venture Capitalists Association (EVCA) and is a Data Advocate for Fintech Sandbox, a non-profit serving fintech entrepreneurs by aggregating data and infrastructure for free during a startup’s development phase.
Sarah is a graduate of the University of Virginia, where she majored in Mechanical Engineering and learned how to fly a Cessna.
Erica Lee is a Senior Associate at F-Prime, focusing on investments in healthcare technology and services companies. Prior to joining F-Prime, she was an investment banking associate at Bank of America Merrill Lynch, where she advised on IPO and M&A transactions across the healthcare IT space.
Erica holds a B.A. from Georgetown University, where she majored in Finance and International Business.
Betsy Mulé is a Principal at F-Prime, where she focuses on early-stage investments in enterprise technology and robotics. Prior to joining F-Prime, she was a strategy consultant at Mars & Co. where she advised Fortune 500 companies across the US, LatAm and Europe.
Betsy is a graduate of MIT where she majored in Chemical-Biological Engineering.
Abdul is a Principal at F-Prime, where he focuses on early-stage investments in B2B software and fintech. Prior to joining F-Prime, Abdul invested in emerging markets-based technology startups and worked with a venture-backed digital banking/payments startup in East Africa. He began his career in financial services where he carried out assurance and valuations services for venture capital, private equity and hedge funds in New York & London.
Abdul holds B.A & B.S degrees from the University of Minnesota. He also holds joint MBA & MPA/ID degrees from Stanford’s Graduate School of Business and the Harvard Kennedy School.
Muz Mansuri joined F-Prime in January 2020 as a Venture Partner and is based in the Cambridge office. Muz will be working with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.
Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.
Muz received his B.Sc. and Ph.D. in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.
Nikhil is a Senior Associate at F-Prime and works across the healthcare sub-sectors including therapeutics, medical technology, life sciences tools, and healthcare IT & services. Prior to joining F-Prime in 2019, Nikhil was an Associate at Audax Group in Boston, where he focused on private equity investments in healthcare and software.
Nikhil is a graduate of the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where he received a B.A. in Biology and a B.S. in Economics from the Wharton School.
Connie is a Principal on the life sciences team at F-Prime based in San Francisco. She focuses primarily on biotechnology investments and also works closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Connie joined F-Prime in 2019, and has been involved in a number of company formation efforts including K36 Tx, Skyline, Pediatrix, and AlphaGen. Prior to joining F-Prime, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.
Connie holds an M.B.A from Harvard Business School, M.S. from the Harvard Department of Stem Cell and Regenerative Biology, and a B.S.E. in Bioengineering from the University of Pennsylvania.
Martin is Principal based in the Cambridge office. Martin’s primary area of interest is in biotechnology investments in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.
Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.
Brett Cook is a Partner at F-Prime, where he focuses on investments in healthcare technology and service companies. At F-Prime, Brett has led or participated in investments in Blue Rabbit (acquired by Wedgewood Pharmacy), Iora Health (acquired by One Medical), PatientPing (acquired by Appriss Heath), VitalWare (acquired by Health Catalyst), 1up Health, AppliedVR, BenchSci, Better Life Partners, Bluebird Kids Health, Equip, Expressable, NOCD, Notable, Paradigm Health, Patina, Proximie, Rippl, and Wellbeam, among others. While at F-Prime, and in collaboration with GV and the Broad Institute, Brett also helped launch and run Project Beacon, a social benefit organization that facilitated more than 1.5 million COVID tests for the Commonwealth of Massachusetts and K-12 schools.
Prior to rejoining F-Prime in 2018, Brett led the finance team at PatientPing (acquired by Appriss Health), a healthcare technology company providing real-time admission and discharge notifications to coordinate patient care. Previously, Brett worked at Aledade and McKinsey & Company.
Brett holds an M.B.A. from Harvard Business School and a B.S.E. in Biomedical Engineering from Duke University.